Physician profile
Tracy M Larson
NPI 1285637207
$697.06
in general payments reported to CMS, 2019-2025
12 companies · $21.53 in 2025
The $21.53 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $50.20 · 2021: $177 · 2022: $46.41 · 2023: $121 · 2024: $49.54 · 2025: $21.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $232.57 | 2019-2023 | Wegovy |
| Abbvie INC. | $130.39 | 2019-2025 | |
| Conmed Corporation | $110.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.90 | 2019-2022 | |
| Pfizer INC. | $32.99 | 2024 | |
| Therapeuticsmd, INC. | $27.15 | 2019 | |
| Aspira Women'S Health INC | $20.39 | 2021 | |
| Kvk-Tech, INC. | $19.12 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $14.63 | 2019 | |
| Ibsa Pharma INC. | $13.71 | 2020 | |
| Currax Pharmaceuticals LLC | $11.99 | 2021 | |
| Forte Bio-Pharma LLC | $4.86 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.